An observational study in Liver Transplantation (LT), Perioperative Care and Prospective Studies, sponsored by Beijing Tsinghua Chang Gung Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Beijing Tsinghua Chang Gung Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 158 studies in Postoperative Complications with a site in China — 46 open to participants now, 53 under way, none of them phase 3. Postoperative Complications · China.
Among the 158 studies in Postoperative Complications with a site in China, this one is the 33rd largest by planned enrollment of the 63 observational ones that give a count, is one of 17 that started in 2026, is one of 63 observational ones, reaches primary completion later than 52 of the 52 other live ones, and was the 158th registered.
1,338 studies on the registry are indexed under Postoperative Complications; 311 are open to participants now.
Browse Postoperative Complications studies →46 of the 158 studies in Postoperative Complications with a site in China are open now. Recruiting first, the newest first:
Sir Run Run Shaw Hospital · Sites in China
Ages 18+
Fudan University · Sites in China
Ages 18–80
Qun Zhao · Sites in China
Ages 18–85
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · Sites in China
Ages up to 18
Wenzhou Medical University · Sites in China
Ages 60+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 201 Postoperative Complications studies recruiting now, 126 (63%) set no upper age limit and 32 (16%) stop at 75 or younger; 24 take children under 18; 25 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
158 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 3 · Phase 4 15
First in 2005; this study’s year is marked. 17 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 450 is above the median of 251 across 539 observational studies indexed under Postoperative Complications.
Median enrollment 200 across the 95 interventional studies, 472 across the 63 observational. Of the 69 that completed or were terminated, 3 (4%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 158 have an industry lead sponsor. The 10 most frequent:
Beijing Tsinghua Chang Gung Hospital is the lead sponsor of 113 studies on the registry; 60 are open to participants now.
Beijing Tsinghua Chang Gung Hospital has 3 studies filed under Postoperative Complications — fewer than ten, so there is no comparison to draw.
15 of the studies in Postoperative Complications with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07646730Tongji HospitalWearable Device-Based Early Warning of Postoperative Complications in Thoracic Surgery | 2026-11-30 |
| NCT04209218Peking University First HospitalIntraoperative Blood Pressure Management and Dexamethasone in Lung Cancer Surgery | 2026-12 |
| NCT03116490Wenzhou Medical UniversityThe Effects of Anesthesia Type on the Prognosis of Hip Fracture Surgery on Elderly Patients | 2026-12 |
| NCT07761390ZhulilingDIEP-MDS for Risk Stratification of Flap Vascular Compromise and Failure in Breast Reconstruction | 2026-12-31 |
| NCT07335042Beijing Tsinghua Chang Gung HospitalPrediction Model for MINS After Major Hepatobiliary Surgery | 2026-12-31 |
Add all 15 to your calendar (.ics) → With an account.
Among the 158 studies in Postoperative Complications with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this observational study (a single-center, prospective, consecutively enrolled clinical cohort) is to establish a cohort of adult liver transplant recipients to correlate, within the same population, the recipients' preoperative status with graft condition, perioperative medical and therapeutic exposures, and dynamic physiological changes, as well as multiorgan outcomes and functional recovery; to identify factors associated with organ injury and difficulties in recovery; and to provide a basis for subsequent clinical validation and intervention studies. The study population consists of adult recipients aged ≥18 years who are scheduled to undergo their first single-liver transplant at this center; continuous enrollment is planned for 5 years, with a target of 450 participants, each followed for 12 months. Recipients undergoing repeat liver transplantation or combined organ transplantation will be included only in a separate expanded registry and analysis.
The primary research questions it aims to address are:
What is the incidence rate and 95% confidence interval of the patient-level composite outcome-defined as all-cause mortality or at least one of the predefined major organ complications (early graft dysfunction/graft failure, new-onset or worsening moderate-to-severe acute kidney injury, new-onset delirium or confirmed acute neurological event, major cardiovascular event, or major pulmonary complication)-within 30 days after the start of the transplant procedure? After accounting for preoperative disease severity, organ function, and graft condition, how are perioperative clinical exposures and physiological changes-such as circulatory, respiratory, temperature, and EEG parameters-associated with multiorgan outcomes and functional recovery at 12 months? Can prespecified dynamic physiological data provide additional information regarding risk or recovery beyond routine clinical data?
This study has no control group; no treatment will be assigned; routine monitoring, testing, or rehabilitation arrangements will not be altered; and no additional blood draws or tissue samples will be collected. Participants will:
Undergo preoperative baseline data collection and assessments of cognition, frailty, functional status, and quality of recovery; some participants will complete the sleep and mood extension modules (PSQI, HADS).
During the perioperative period, participants will allow the research team to record clinically generated treatment exposures and multimodal monitoring data, including circulatory, respiratory, temperature, and EEG parameters.
Participants will complete relevant follow-up visits and functional assessments on postoperative days 7, 30, and 90, as well as at 6 and 12 months, including the QoR-15, DAH-30/90, and assessments of cognition, frailty, functional status, and quality of life.
Follow-up should preferably be conducted in conjunction with routine follow-up visits; when necessary, survival, hospitalization, and living conditions may be verified via approved telephone contact. Additional clinical testing using residual serum and tissue samples is optional; refusal to provide these samples will not affect enrollment in the study.
This is a single-center study, and the study population is sourced from Beijing Tsinghua Changgung Hospital. Adult recipients (aged ≥18 years) scheduled to undergo primary single liver transplantation at this center are consecutively screened during waitlist registration, inpatient preoperative evaluation, or pre-transplant preparation. With an estimated 100 adult liver transplant surgeries performed annually at this center, approximately 450 recipients are planned to be enrolled consecutively over a 5-year period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
(Note: Patients undergoing emergency transplantation, preoperative hepatic encephalopathy, intensive care, mechanical ventilation, and renal replacement therapy are eligible. Donor type and disease severity will be retained as stratification information.)
Exclusion Criteria:
(Note: Patients undergoing re-transplantation and combined organ transplantation may enter a separate extended registry within the same ethical framework, but will not be mixed into the primary analysis cohort of primary single liver transplantation and its sample size denominator.)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
No intervention
Number of participants with all-cause mortality or at least one major organ complication within 30 days after the start of transplant surgery, assessed according to preset clinical criteria (e.g., Olthoff definition, KDIGO criteria).
Time frame: From the start of surgery to 30 days postoperatively.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Started Oct 2026 (actual). Primary completion is estimated for Oct 2031, 60 months after the start.
Of 277 non-industry observational studies under Postoperative Complications, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 39. This study's planned 60 months is above that.
Counting every sponsor, half of 282 studies reached it within 22 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Beijing Tsinghua Chang Gung Hospital →